Skip to content

Study · Randomized controlled trial · 2024

3 results

[The effectiveness of rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology].

Degtyareva VG, Drobyshev VA, Poteryaeva EL

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2024

PMID39731376 (opens in a new tab)DOI10.17116/jnevro202412412186 (opens in a new tab)PepBankPUB-39731376
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with hypoxic neuropsychiatric pathology, the frequency and severity of symptoms were reduced after two Cortexin courses compared with subgroups 1B and 2B.

    In plain wordsIn infants with brain damage from low oxygen, symptoms were less frequent and severe after Cortexin than in groups 1B and 2B.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseFrequency and severity of symptoms
    Study

    n: not reported in source

    Comparator
    Subgroups 1B and 2B
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 2 courses with an interval of 3 monthsAs given in this study (human).

    Source sentences

    Summary
    In children of subgroups 1A and 2A, the frequency and severity of symptoms after therapy differed statistically significantly from those in patients of groups 1B and 2B.
    3 context sentences
    Summary · context
    Patients of both groups were randomized into 2 subgroups: patients of subgroups 1A and 2A received 2 courses of Cortexin administration with an interval of 3 months.
    Summary · context
    All patients received treatment in accordance with clinical guidelines.
    Summary · context
    Conducting two treatment courses with the inclusion of the drug Cortexin leads to a significant reduction in the frequency and severity of manifestations of myotonic and hypertensive-hydrocephalic syndromes in children with both acute and chronic hypoxic-ischemic central nervous system damage.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with hypoxic neuropsychiatric pathology, symptom severity decreased with Cortexin compared with subgroups 1B and 2B.

    In plain wordsChildren with hypoxic neuropsychiatric pathology had less severe symptoms with Cortexin than children in comparison subgroups.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseSymptom severity
    Study

    n: not reported in source

    Comparator
    Subgroups 1B and 2B
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 2 courses with an interval of 3 monthsAs given in this study (human).

    Source sentences

    Summary
    In children of subgroups 1A and 2A, the frequency and severity of symptoms after therapy differed statistically significantly from those in patients of groups 1B and 2B.
    3 context sentences
    Summary · context
    Patients of both groups were randomized into 2 subgroups: patients of subgroups 1A and 2A received 2 courses of Cortexin administration with an interval of 3 months.
    Summary · context
    All patients received treatment in accordance with clinical guidelines.
    Summary · context
    Conducting two treatment courses with the inclusion of the drug Cortexin leads to a significant reduction in the frequency and severity of manifestations of myotonic and hypertensive-hydrocephalic syndromes in children with both acute and chronic hypoxic-ischemic central nervous system damage.

Studies that did not test the peptide alone1

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

  1. 03HumanNot a test of Cortexin (cortical polypeptide complex) aloneRandomized controlled trialEfficacy outcome

    In children with hypoxic pathology, bioelectric activity in the 10-12 Hz range and signal amplitude increased during Cortexin use, but the reported subgroup labels make treatment attribution uncertain.

    In plain wordsChildren showed increased brain electrical activity and signal amplitude during Cortexin use, but inconsistent subgroup labels make attribution uncertain.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseBioelectric activity (10-12 Hz) and signal amplitude
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Measurements

    Proportion with increased activity
    73.4%
    subgroup 1A
    Proportion with increased activity
    71.3%
    subgroup 1B

    Source sentences

    Summary
    Against the background of Cortexin use, 73.4% of the examined subgroups 1A and 71.3% - 1B showed an increase in bioelectric activity in the range of 10-12 Hz, an increase in signal amplitude.
    2 context sentences
    Summary · context
    Patients of both groups were randomized into 2 subgroups: patients of subgroups 1A and 2A received 2 courses of Cortexin administration with an interval of 3 months.
    Summary · context
    All patients received treatment in accordance with clinical guidelines.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.